BridgeBio Pharma DB:2CL Stok Raporu Şirket Finansalları + 18 Analistler
BridgeBio Pharma, Inc.
DB:2CL Stok Raporu
2CL Stoklara Genel Bakış Ticari aşamada bir biyofarmasötik şirketi olan BridgeBio Pharma, Inc. genetik hastalıklardan ve kanserlerden muzdarip hastaları tedavi etmek için dönüştürücü ilaçlar keşfeder, yaratır, test eder ve sunar.
Ödüller Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör BridgeBio Pharma, Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BridgeBio Pharma Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$25.05 52 Haftanın En Yüksek Seviyesi US$39.72 52 Haftanın En Düşük Seviyesi US$21.00 Beta 1.09 11 Aylık Değişim 9.92% 3 Aylık Değişim 14.75% 1 Yıllık Değişim -1.80% 33 Yıllık Değişim -38.90% 5 Yıllık Değişim 1.83% Halka arzdan bu yana değişim 6.73%
Son Haberler & Güncellemeler
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Oct 01
BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024 Aug 31
BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney Aug 19
Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023) Aug 02
BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Jul 23
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Jun 19 Daha fazla güncelleme görün
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Oct 01
BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024 Aug 31
BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney Aug 19
Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023) Aug 02
BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Jul 23
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Jun 19
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia Jun 05
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population May 14
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.92 loss in 1Q 2023) May 02
BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024 Apr 28
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Apr 09 BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 07
BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 06
BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering. Mar 05
Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022) Feb 23
New major risk - Financial position Feb 23
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy Feb 06
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months Feb 03
BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine Jan 11
BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia Dec 14
Now 21% undervalued Dec 12
BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Nov 14
Third quarter 2023 earnings released: US$1.08 loss per share (vs US$0.93 loss in 3Q 2022) Nov 03
BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9 Oct 10 BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors Sep 26
Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia Sep 07
BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023 Aug 28
New minor risk - Financial position Aug 04
Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022) Aug 03
Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study Aug 01
Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy Jul 18
BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia Jun 21
First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.35 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021) Feb 24
Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 Dec 24
Third quarter 2022 earnings released: US$0.93 loss per share (vs US$1.06 loss in 3Q 2021) Nov 04
BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Oct 15
BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society Oct 14
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib) Oct 12
BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium Oct 08
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Sep 21
BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671 Aug 19
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Aug 11
Second quarter 2022 earnings released: US$0.067 loss per share (vs US$0.66 loss in 2Q 2021) Aug 05
BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2 Jul 28
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A Jul 27
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers Jun 28
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease Jun 23
BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Jun 14
BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations Jun 11
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias May 28 BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01 May 21
BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022 May 02
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Apr 04
Insider recently bought €75k worth of stock Mar 17
Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO). Mar 10
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 25
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) Jan 28
Independent Director recently bought €264k worth of stock Jan 01
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study Dec 28
LianBio and BridgeBio Pharma, Inc. Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors Aug 26
Bridgebio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to Its Board of Directors Aug 19
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1 Jun 02
QED Therapeutics and Partner Helsinn Group Announce FDA Approval of Truseltiq™ (infigratinib) for Patients with Cholangiocarcinoma May 29
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia May 15
Forecast to breakeven in 2025 May 14
BridgeBio Pharma, Inc. (NasdaqGS:BBIO) announces an Equity Buyback for $150 million worth of its shares. May 12
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting Mar 21
New 90-day high: €59.72 Mar 11
BridgeBio Pharma, Inc. and affiliate Origin Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A Mar 01
Full year 2020 earnings released: US$3.80 loss per share (vs US$2.48 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
BridgeBio Pharma, Inc. and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) Feb 20
New 90-day high: €59.32 Feb 10
Bridgebio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of Bbp-681 for Venous, Lymphatic, and Venolymphatic Malformations Feb 03
BridgeBio Pharma, Inc. (NasdaqGS:BBIO) completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc. (NasdaqGS:EIDX). Jan 28
New 90-day high: €56.96 Jan 19
BridgeBio Pharma, Inc. Announces Executive Changes Jan 05
UC San Francisco Foundation and Bridgebio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases Dec 25
Board Member recently sold €108k worth of stock Dec 18
Bridgebio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease Dec 10
New 90-day high: €44.47 Dec 09
BridgeBio Pharma and QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma Dec 02
Insider recently sold €3.6m worth of stock Nov 19
New 90-day high: €35.90 Nov 14
BridgeBio Pharma, Inc. and Navire Pharma, Inc. Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations Nov 14
Revenue misses expectations Nov 06 Hissedar Getirileri 2CL DE Biotechs DE Pazar 7D 5.9% -2.2% 1.1% 1Y -1.8% -17.1% 13.5%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2CL geçen yıl % -17.1 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: 2CL geçen yıl % 13.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 2CL's price volatile compared to industry and market? 2CL volatility 2CL Average Weekly Movement 7.4% Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 2CL hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 2CL 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Ticari aşamada bir biyofarmasötik şirketi olan BridgeBio Pharma, Inc. genetik hastalıklardan ve kanserlerden muzdarip hastaları tedavi etmek için dönüştürücü ilaçlar keşfeder, yaratır, test eder ve sunar. Geliştirme programlarındaki ürünleri arasında TTR amiloidozu veya transtiretin amiloid kardiyomiyopatisi (ATTR-CM) tedavisi için Faz 3 klinik çalışmasında olan yeni nesil oral küçük moleküllü tama yakın bir TTR stabilizatörü olan AG10 bulunmaktadır; akondroplazili çocukların tedavi seçeneği için Faz 3 çift kör, plasebo kontrollü pivotal çalışmada olan oral FGFR1-3 selektif tirozin kinaz inhibitörü olan düşük doz infigratinib; ve 21-hidroksilaz eksikliği veya 21OHD'den kaynaklanan konjenital adrenal hiperplazi veya KAH tedavisi için Faz 1/2 klinik çalışmada olan bir AAV5 gen transferi ürün adayı olan BBP-631. Şirket ayrıca, otozomal dominant hipokalsemi tip 1 veya ADH1 tedavisi için faz 3 klinik çalışmada olan kalsiyum algılama reseptörünün veya CaSR'nin küçük moleküllü bir antagonisti olan Encaleret'i ve uzuv-kuşak kas distrofisi tip 2I / R9 (LGMD2I / R9) tedavisi için Faz 3 klinik çalışmada olan bir glikozilasyon substrat pro-ilacı olan BBP-418'i geliştirmektedir.
Daha fazla göster BridgeBio Pharma, Inc. Temel Bilgiler Özeti BridgeBio Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2CL temel i̇stati̇sti̇kler Piyasa değeri €4.78b Kazançlar(TTM ) -€425.95m Gelir(TTM ) €205.67m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2CL gelir tablosu (TTM ) Gelir US$219.12m Gelir Maliyeti US$2.39m Brüt Kâr US$216.73m Diğer Giderler US$670.55m Kazançlar -US$453.82m
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -2.41 Brüt Marj 98.91% Net Kâr Marjı -207.11% Borç/Özkaynak Oranı -158.7%
2CL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
